AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company.
In 2013, it moved its headquarters to Cambridge, United Kingdom, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015, it was the eighth-largest drug company in the world based on sales revenue.
AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).
article11 April 2024 | By Eric Flynn (Siemens UK & Ireland)
Digitalisation could dramatically streamline the process of setting up and running pharmaceutical manufacturing processes, bringing sustainability and cost benefits, as Eric Flynn, Head of Pharmaceutical and Life Sciences at Siemens, explains.
news18 March 2024 | By Catherine Eckford (European Pharmaceutical Review)
As part of the proposed acquisition, Alexion (AstraZeneca Rare Disease) will add a therapeutic to its pipeline that has potential to “shift the treatment paradigm” in hypoparathyroidism.
news7 March 2024 | By Catherine Eckford (European Pharmaceutical Review)
A joint government and industry investment of £92 million intended to expand UK medicine manufacturing facilities, form part of a new £360 million funding package from the UK government.
news21 February 2024 | By Catherine Eckford (European Pharmaceutical Review)
Results from AstraZeneca’s LAURA Phase III trial “represent a major advance for [certain] patients with Stage III EGFR-mutated lung cancer".
news14 February 2024 | By Catherine Eckford (European Pharmaceutical Review)
The global pharmaceutical suspensions market is set to value $83.8 billion by 2032, due to the systems having key benefits such as supporting patient compliance.
news7 February 2024 | By Catherine Eckford (European Pharmaceutical Review)
Investment in the US manufacturing facility will accelerate AstraZeneca’s ambition to make next-generation cell therapy a reality, the company asserts.
news2 January 2024 | By Catherine Eckford (European Pharmaceutical Review)
The new acquisition grants AstraZeneca rights to a new CAR-T cell therapy with a differentiated manufacturing process that could provide a potential best-in-class blood cancer treatment.
news6 December 2023 | By Catherine Eckford (European Pharmaceutical Review)
A study evaluating the combination of a PD1 inhibitor with dupilumab enabled one out of six lung cancer patients to achieve a near-complete clinical response two months post-treatment, a paper states.
news29 November 2023 | By Catherine Eckford (European Pharmaceutical Review)
The new industry collaboration aims to help decarbonise the global supply chain by focusing on the energy-intensive pharmaceutical manufacturing that takes place in China and India.
news27 November 2023 | By Catherine Eckford (European Pharmaceutical Review)
Alexion’s intravenous enzyme replacement therapy has been recommended for the ultra-rare disease by the National Institute for Health and Care Excellence (NICE).
article26 October 2023 | By Catherine Eckford (European Pharmaceutical Review), Dr Mark Rutstein (Daiichi Sankyo)
Dr Mark Rutstein, Senior Vice President, Head of Oncology Clinical Development at Daiichi Sankyo, highlights key data about the company’s antibody-drug conjugate (ADC) being investigated for breast and lung cancer, and shares insight into why ADCs could replace current standards of care in oncology.
news12 October 2023 | By Catherine Eckford (European Pharmaceutical Review)
With over $7 billion sales predicted by 2029, AstraZeneca’s Tagrisso is set to lead the lung cancer small molecule treatment market, according to GlobalData.
article12 October 2023 | By Catherine Eckford (European Pharmaceutical Review)
This article outlines the recent progress of several major new manufacturing facilities that will be central in supporting the production of innovative therapies in Europe.
article2 October 2023 | By CPhI
CPHI Barcelona takes place in October 2023, covering a wide range of topics from next generation biomanufacturing and formulation to sustainability.
news14 September 2023 | By Catherine Eckford (European Pharmaceutical Review)
Part of AstraZeneca's £100 million renewable energy commitment involves a 15-year partnership to establish the UK’s first unsubsidised industrial-scale supply of biomethane, supporting sustainable pharmaceutical manufacturing.